

**CURRICULUM VITAE:****JETZE J. TEPE (he/him/his)**

---

Department of Chemistry  
Michigan State University  
East Lansing, MI 48824  
E-mail: tepe@chemistry.msu.edu

**EDUCATION**

<b>Post-Doctoral Research</b>	Colorado State University, Fort Collins, Colorado, 1998-2000
<b>Ph.D. Chemistry</b>	University of Virginia, Charlottesville, Virginia, 1998
<b>B.S. Chemistry</b>	Jacksonville University, Jacksonville, Florida, 1992

**Leadership Experience:**

- From 2021-present, Scientific founder and director of Portera Therapeutics INC. Portera Therapeutics is pursuing the clinical development of 20S proteasome enhancers for the therapeutic treatment of cancer and neurodegenerative disorders.
- From 2015-present, University drug discovery steering committee. This University committee identifies research groups on campus and provides advice and assist the PI(s) to enhance the translational potential of their discovery.
- From 2006-2012, the translational clinical efficacy of one of our leads was further explored by TCH Pharmaceuticals INC, Ann Arbor, MI, where I served as Co-Founder and Vice President of Research.

**Current research:** Research in our lab is an interdisciplinary blend of medicinal chemistry and pharmacology. Specifically, our research focus is on targeting “undruggable targets” using small molecules to treat neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease, and ALS) and cancer (multiple myeloma). We are one of the first to explore the enhancement of proteolytic degradation of undruggable proteins by small molecule activation of the 20S subcomplex of the proteasome. As part of this effort, our lab develops new heterocyclic reactions to synthesize natural products and their drug-like derivatives. Following their synthesis, the compounds are subsequently interrogated for their potential clinical significance *in vitro*, cells and neurons in the lab, with a specific focus on the classical “undruggable” proteins including  $\alpha$ -synuclein, tau, amyloid- $\beta$ , dipeptide repeats and others.

*Current funding:* All projects are currently funded through the following agencies:

NIH 1 R21 AG076994-01		04/01/22-03/31/24
PI: Tepe; Title: Overcoming proteasome impairment with small molecules		
Funded: \$ 398,909		
NIH R01 AG066223-01A1		09/15/19-05/31/23
PI: Tepe; Title: Small molecule induced proteolytic destruction of intrinsically disordered proteins		
Funded: \$1,473,114		
NIH R01 AG066223-01A1	-DEI Suppl.	03/15/21-05/31/23
Funded: \$132,165		
NIH R01 AG066223-01A1	-DEI Suppl.	12/01/21-05/31/23
Funded: \$91,489		
NIH 1R61NS111347-01A1 (IGNITE grant)		12/01/19-11/30/23
PI: Tepe; Title: Development of cellular HTS for 20S proteasome enhancers		
Funded: \$1,096,391		
NIH 1 R21 AG0613061306-01		01/15/20-11/30/22
PI: Tepe; Multiparameter optimization of new phenothiazines for proteasome activation		
Funded: \$401,735		

## AWARDS

- William J. Beal Outstanding Faculty Award, MSU, 2022
- MSU Inventor of the Year Award, 2022
- AbbVie Innovation Midwest Award, 2021
- Outstanding Faculty Award, MSU College of Natural Sciences, 2021
- International Myeloma Foundation, Senior Brian D. Novis Award, 2019
- International Myeloma Foundation, Senior Brian D. Novis Award, 2013
- Multiple Myeloma Research Foundation (MMRF), Senior Award, 2010
- Multiple Myeloma Research Foundation (MMRF), Senior Award, 2008
- American Cancer Society Research Scholar Award, 2003-2008
- Teacher-Scholar Award, CNS, Michigan State University, 2005
- Petroleum Research Fund Award, American Chemical Society, 2002
- Alfred Burger Fellowship, Senior Thesis Fellowship, University of Virginia, 1997
- Dean's Reserve Fellowship, University of Virginia, 1994

## POSITIONS

2021-present	Scientific Founder, Portera Therapeutics INC
2021-2022	Experimental therapeutics task force committee member
2020-2022	Expert litigation consultant, Takeda Pharmaceuticals
2020	Full Professor of Chemistry & Pharmacology and Toxicology
2019	Guest Editor, <i>Molecules</i> , Special Issue on Proteasome Regulators
2018- present	Editorial board member, <i>Molecules</i>
2017-present	Faculty, Department of Pharmacology & Toxicology, MSU
2016	External reviewer of NIDDK, Bioorganic Chemistry laboratory.
2016-present	NIH-T32 steering committee (Integrative Pharmacological Sciences Training Program)
2016-present	Mentor NIH-T32 (Integrative Pharmacological Sciences Training Program)
2016	Ad Hoc member, MMRF grant review committee
2015	Ad Hoc member, MMRF grant review committee
2015-present	MSU drug discovery steering committee
2013-2016	Mentor NIH-T34 MARC (for underrepresented students in biomedical sciences)
2006-2015	Editorial board member, <i>Current Bioactive Compounds</i>
2006	Associate Professor of Chemistry, Michigan State University
2006-2012	Vice President of Research, TCH Pharmaceuticals Inc, Ann Arbor, MI
2009-2010	Guest Editor, <i>Current Organic Synthesis</i> , Special Issue: Cycloaddition Reactions
2007-2008	Guest Editor, <i>Current Bioactive Compounds</i> , Special Issue: Anti-cancer Therapies
2006	Co-Founder, TCH Pharmaceuticals Inc, Ann Arbor, MI
2005-present	Ad Hoc member, NIH study sections
2004-2005	Chair, Local Section American Chemical Society
2004-2005	Scientific Consultant, Valent Technologies
2003-2005	Scientific Consultant, ChemGenex Therapeutics
2000-2006	Assistant Professor of Chemistry, Michigan State University

## PROFESSIONAL SERVICE

2021-current	Scientific Founder, Portera Therapeutics
2020-2022	Expert litigation consultant, Takeda Pharmaceuticals
2006-2012	Co-Founder & VP of Research, TCH Pharma Inc, Ann Arbor, MI

## Symposium/Conferences:

2022	Section Chair: ACS regional conference, Michigan
2016	Section Chair: Medchem. & CADD conference Phoenix, Arizona

- 2015 Ad-Hoc Advisory Board Member of 2<sup>nd</sup> Annual Drug Discovery Congress.  
 2014 Section Chair: MedChem. & CADD conference San Francisco, California.  
 2012 Co-Organizer: Symposium University of Virginia, Dedication to Prof. T. Macdonald. Articles published in special issue of Bioorganic and Medicinal Chemistry Letters, **2012** issue 22.  
 2004 Section Chair: Gordon Conference Heterocyclic Chemistry.

#### NIH Study Sections:

2019: February	BST-55 (High Throughput Screening)
2018: June	BST-55 (High Throughput Screening)
2016: November	BCMB-G (Biological Chemistry and Macromolecular Biophysics)
2015: November	CDDT (Cancer Drug Development and Therapeutics)
2015: March	NCI Omnibus Review (Drug Development and Targeting)
2014: October	SBCB (Synthetic and Biological Chemistry B)
2014: March	CDDT (Cancer Drug Development and Therapeutics)
2013: November	CDDT (Cancer Drug Development and Therapeutics)
2010: March	FO4A (Synthetic and Biological Chemistry Fellowships)
2009: August	BCMB (Biological Chemistry and Macromolecular Biophysics)
2008: March	F04A (Synthetic and Biological Chemistry Fellowships)
2006: July	F04A (Synthetic and Biological Chemistry Fellowships)
2005: November	F04A (Synthetic and Biological Chemistry Fellowships)
2005: July	F04A (Synthetic and Biological Chemistry Fellowships)

#### Ad hoc reviewer:

**Grants:** NIH, NSF, PRF, Wellcome Trust Fund, US Civilian Research & Development Foundation.

**Journals:** *Science Reports, Journal of the American Chemical Society, Nature protocols, Bioorganic & Medicinal Chemistry Letters, Bioorganic & Medicinal Chemistry, Organic Letters, European Journal of Medicinal Chemistry, Journal of Combinatorial Chemistry, Journal of Medicinal Chemistry, Australian Journal of Chemistry, ChemMedChem, Journal of Organic Chemistry, European Journal of Organic Chemistry, Tetrahedron, Tetrahedron Letters, Current Bioactive Compounds, Current Organic Synthesis.*

#### ► PEER REVIEWED PUBLICATIONS

- Mehedi, Md Shafaat Al; George, Dare E.; Tepe, Jetze J. Sc(OTf)<sub>3</sub> mediated one-pot synthesis of 3,4-disubstituted 1H-pyrazoles and 3,5-disubstituted pyridines from hydrazine or ammonia with epoxides. **2022**, submitted.
- Njomen, Evert; Vanecek, Allison; Lansdell, Theresa A.; Bernard, Matt P.; Yang, Ya-Ting; Schall, Peter Z.; Isaac, Daniel; Omar Alkharabsheh; Al-Janadi Anas; Giletto, Matthew B.; Ellsworth, Edmund; Taylor, Catherine; Tang, Terence; Lau, Sarah; Bailie, Marc; Bernard; Jamie J.; Yuzbasiyan-Gurkan, Vilma and Tepe, Jetze J., 20S proteasome enhancement targets c-MYC and induces in vivo anti-tumor efficacy, *Biomedicines*, **2022**, in print.
- Staerz, S. D.; Jones, C. L. and Tepe, Jetze J. Design, Synthesis and Biological Evaluation of Potent 20S Proteasome Activators for Treatment of Neurodegenerative Diseases. *Journal of Medicinal Chemistry*, **2022**, in print.
- Savelson, Evan; Tepe, Jetze J. One-Pot Friedel–Crafts/Robinson–Gabriel Synthesis of the Indole-Oxazole Scaffold and its Application to the Synthesis of Breitfussins C, G, and H, *Journal of Organic Chemistry*, **2022**, in print, <https://doi.org/10.1021/acs.joc.2c00033>.
- Gao, Kaifu; Wang, Rui; Chen, Jiahui; Tepe, Jetze J.; Huang, Faqing; and Wei, Guo-Wei. Perspectives on SARS-CoV-2 Main Protease Inhibitors. *Journal of Medicinal Chemistry*, **2021**, *64*, 16922–16955.
- George, D. E. and Tepe, Jetze J. Advanced in Proteasome Enhancement by Small Molecules. *Biomolecules*, **2021**, *11*, 1789.
- Keel, Katarina L.; and Tepe, Jetze J. Total Synthesis of Nortopsentin D via a Late-Stage Pinacol-like Rearrangement, *Organic Letters*, **2021**, *23*, 5368-5372.

8. Fiolek, Taylor J.; Keel, Katarina L. and Tepe, Jetze J. Fluspirilene analogs activate the 20S proteasome and overcome proteasome impairment by intrinsically disorder protein oligomers, *ACS Chemical Neuroscience* **2021**, *12*, 1438–1448.
9. Fiolek, Taylor J.; Magyar, Christina L.; Wall, Tyler J.; Davies, Steven B.; Campbell, Molly V.; Savich Christopher J.; Tepe, Jetze J. and Mosey, R. Adam, Dihydroquinazolines enhance 20S proteasome activity and induce degradation of alpha-synuclein, an intrinsically disordered protein associated with neurodegeneration, *Bioorganic and Medicinal Chemistry Letters*, **2021**, *36*, 127821.
10. Njomen, Evert; Lansdell, Theresa A.; Benham, Vanessa; Bernard, Matt P.; Yang, Ya-Ting; Schall, Peter Z.; Isaac, Daniel; Omar Alkharabsheh; Al-Janadi Anas; Giletto, Matthew B.; Ellsworth, Edmund; Taylor, Catherine; Tang, Terence; Lau, Sarah; Bailie, Marc, Bernard; Jamie J.; Yuzbasiyan-Gurkan, Vilma and Tepe, Jetze J., 20S proteasome enhancement targets c-MYC and induces in vivo anti-tumor efficacy, *BioRxiv*, **2020**, <https://doi.org/10.1101/2020.08.24.265470>.
11. Hubbell, Grace E. and Tepe, Jetze J. Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors, *RCS Chemical Biology* **2020**, *1*, 305-332.
12. Keel, Katarina L. and Tepe, Jetze J. The preparation of (4H)-imidazol-4-ones and their application in the total synthesis of natural products, *Organic Chemistry Frontiers* **2020**, *7*, 3284 - 3311
13. Mehedi, Md Shafaat Al and Tepe, Jetze J. Recent Advances in the Synthesis of Imidazolines (2009-2020), *Adv. Synth. Catal.* **2020**, *362*, 4189-4225.
14. Mehedi, Md Shafaat Al and Tepe, Jetze J. Sc(OTf)<sub>3</sub> Mediated One-Pot Synthesis of 2,3-Disubstituted Quinolines from Anilines and Epoxides, *Journal of Organic Chemistry*, **2020**, *85*, 10, 6741–6746.
  - Article highlighted in *Synfacts* **2020**; *16*, 898. DOI: 10.1055/s-0040-1706834
15. Jones, Corey and Tepe, Jetze, Proteasome Activation to Combat Proteotoxicity, *Molecules*, **2019**, *24*, 2841. PMID 31387243
  - Special Issue: *Proteasome Regulators: Activators and Inhibitors*
16. Njomen, Evert and Tepe, Jetze, Regulation of Autophagic Flux by the 20S proteasome. *Cell, Chemical Biology*, **2019**, *26.*, 1283-1294. PMID31327703
17. Njomen, Evert and Tepe, Jetze J. Proteasome activation as a new therapeutic approach to target proteotoxic disorders, *Journal of Medicinal Chemistry*, **2019**, *62*, 6469-6481. PMID30839208
  - Article recommended by *F1000Prime*
18. Mehedi, Md Shafaat Al and Tepe, Jetze J. Diastereoselective one-pot synthesis of oxazolines using sulfur ylides and acyl imines, *Journal of Organic Chemistry*, **2019**, *84*, 7219-7226. PMID31117573
19. Giletto, Matthew B; Osmulski, Pawel A.; Jones, Corey L.; Gaczynska Marie E. and Tepe, Jetze J. Pipecolic esters as new templates for proteasome inhibition, *Organic & Biomolecular Chemistry*, **2019**, *17*, 2734-2746. PMID 307784535
20. Gao, Shuang, Bethel, Travis K. Kakeshpour T.; Hubbell, Grace E., Jackson, James, E. and Tepe, Jetze J. Substrate Controlled Regioselective Bromination of 2-AcyI Pyrroles Using Tetrabutyl Ammonium Tribromide (TBABr<sub>3</sub>), *Journal of Organic Chemistry*, **2018**, *83*, 9250-9255. PMID: 29969032
21. Njomen, Evert; Osmulski, Pawel A.; Jones, Corey L; Lansdell, Theresa A. Gaczynska, Maria E. and Tepe, Jetze J. Small Molecule Modulation of Proteasome Assembly, *ACS Biochemistry*, **2018**, *57*,4214-4224. PMID: 29897236
  - Article recommended by *F1000Prime*
22. Jones, Corey L.; Njomen, Evert; Sjogren B.; Dexheimer, Thomas S. and Tepe, Jetze J. Small molecule enhancement of 20S proteasome activity targets intrinsically disordered proteins. *ACS Chemical Biology* **2017**, *15*;12(9):2240-2247. PMID: 28719185.
23. McDaniel, Tanner J.; Lansdell, Thereasa A.; Dissanayake, Amila A.; Azevedo, Lauren M.; Claes, Jacob; Odom, Aaron L. and Tepe, Jetze J. Substituted quinolines as noncovalent proteasome inhibitors, *Bioorganic and Medicinal Chemistry*, **2016**, *24*, 2441-2450. PMID: 27112450.
24. Zaib, Rahman S. and Tepe, Jetze J. A concise total synthesis of hymenialdisine, *Tetrahedron Letters*, **2015**, *56*, 3011-3013.
  - Article selected for: *Special Issue dedicated to Prof. H. Wasserman.*

25. Kuszpit, Michael R.; Giletto, Matthew B.; Jones, Corey L.; Bethel, Travis K. and Tepe, Jetze J. Hydroxyamination of olefins using Br-N-(CO<sub>2</sub>Me)<sub>2</sub>. *Journal of Organic Chemistry*, **2015**, 80, 1440-1445. PMID: 25574949
26. Beck, Philipp; Lansdell, Theresa A.; Hewlett, Nicole M.; Tepe, Jetze J. and Groll, Michael, Indolo-phakellins as  $\beta$ 5-specific noncovalent proteasome inhibitors, *Angewandte Chemie Int. Ed.* **2015**, 54, 2830-2833. PMID: 25581903.
- Article highlighted by editors as: *Hot Paper*.
27. Basson, Marc D.; Zeng B; Downey C; Siriveluprabhakara S, Tepe, Jetze J. Increased extracellular pressure stimulates tumor proliferation by a mechanosensitive calcium channel and PKC- $\beta$ . *Molecular Oncology*, **2015**, 9, 513-526. PMC4487881
28. Hewlett, Nicole M. and Tepe, Jetze J. 2-Phenyl oxazolone. *Electronic Encyclopedia of Reagents for Organic Synthesis*, **2014**, 1-3.
29. Azevedo, Lauren M.; Lansdell, Theresa A.; Ludwig, Jacob R.; Mosey, R. Adam; Woloch, Daljinder K.; Cogan, Dillon P.; Patten, Gregory P.; Kuszpit, Michael R.; Fisk, Jason S. and Tepe, Jetze J. Inhibition of the human proteasome by imidazoline scaffolds. *Journal of Medicinal Chemistry*, **2013**, 56, 5974-5978. PMC3844044
- Article Highlighted in *Science Business Exchange SciBX* 6(28), July 25, 2013
30. Lansdell, Theresa A.; Hurchla, Michelle A.; Xiang, J.; Hovde, S.; Weilbaeher, Katherine N.; Henry, R. William; Tepe, Jetze J. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo. *ACS Chemical Biology*, **2013**, 8, 578-587. PMC3600058
- Article Highlighted: ACS Chemical Biology editors highlight article from Volume 8, Issue 3 and speak with author Jetze Tepe on itunes podcast, March 2013.
  - Article recommended by *F1000Prime*
31. Nguyen, Thu N.T.; Saleem, Rahman S. Z.; Luderer, Micah, J.; Tepe, Jetze J. Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors. *ACS Chemical Biology*, **2012**, 7, 172-184. PMID: 22004065
32. Lansdell, Theresa A.; O'Reilly, Sandra; Woolliscroft, Tracey; Azevedo, Lauren M.; Kahlon, Daljinder K.; Hovde, Stacy; McCormick, J. Justin; Henry, R. William; Cornicelli, Joseph A.; Tepe, Jetze J. Non-competitive inhibition of the human proteasome attenuates collagen-induced arthritis. *Bioorganic & Medicinal Chemistry Letters*, **2012**, 22, 4816-4819. PMID: 22682057
33. Lansdell, Theresa A.; Hewlett, Nicole M.; Skoumbourdis, Amanda P.; Fodor, Matthew D.; Seiple, Ian B.; Su, Shun; Baran, Phil. S.; Feldman, Ken S.; Tepe, Jetze J. Palau'amine and Related Oroidin-alkaloids Dibromophakellin and Dibromophakellstatin Inhibit the Human 20S Proteasome. *Journal of Natural Products*, **2012**, 75, 980-985. PMC3367325
- Article recommended by *F1000Prime*, 17 Jul 2018; F1000Prime.com/717748071
34. Saleem, Rahman Shah Zaib; Lansdell, Theresa A.; Tepe, Jetze J. Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors. *Bioorganic & Medicinal Chemistry* **2012**, 20, 1475-1481. PMID: 20481587
35. Hewlett, Nicole M.; Tepe, Jetze J. Total synthesis of the natural product ( $\pm$ )-dibromophakellin and analogues. *Organic Letters*, **2011**, 13, 4550-4553. PMC3162990
36. Nguyen, T. N. T.; Tepe, J. J, Checkpoint kinase inhibitors. *Current Medicinal Chemistry*, **2011**, 18, 4368-4374.
37. Qu, Ke; Fisk, Jason S.; Tepe, Jetze J. Azomethine ylide mediated inversion of configuration of quaternary imidazoline carbon: converting *trans*- to its *cis*- imidazolines. *Tetrahedron Letters*, **2011**, 52, 4840-4842. PMC3157035
38. Frawley Cass, Samantha M.; Tepe, Jetze J. Identification of phosphoproteins and their impact as biomarkers in cancer therapeutics. *Current Signal Transduction Therapy*, **2011**, 6, 113-140.
39. Kuszpit, Michael R.; Wulff, William D.; Tepe, Jetze J. One-Pot Synthesis of 2-Imidazolines via the Ring Expansion of Imidoyl Chlorides with Aziridines. *Journal of Organic Chemistry*, **2011**, 76, 2913-2919. PMC3074022

40. Saleem, Rahman Shah Zaib; Tepe, Jetze J., Synthesis of 1,2,4-triazolines and triazoles utilizing oxazolones. *Journal of Organic Chemistry*, **2010**, 75, 4330-4332.
- Article highlighted in *Synfacts*, **2010**, 0997.
41. Tepe, Jetze J., Recent advances in cycloaddition reactions in natural product synthesis. *Current Organic Synthesis*, **2010**, 7, 311.
42. Wang, Wei-Han; Palumbo, Amanda M.; Tan, Yu-Jing; Reid, Gavin E.; Tepe, Jetze J.; Bruening, Merlin L., Identification of p65-Associated Phosphoproteins by Mass Spectrometry after On-Plate Phosphopeptide Enrichment Using Polymer-oxotitanium Films. *Journal of Proteomic Research*, **2010**, 9, 3005-3015.
43. Hupp, Christopher D.; Tepe, Jetze J. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Hydrochloride-Mediated Oxazole Rearrangement: Gaining Access to a Unique Marine Alkaloid Scaffold. *Journal of Organic Chemistry*, **2009**, 74, 3406-3413
44. Frawley Cass, Samantha M.; Reid, Gavin E.; Tepe, Jetze J., Synthesis of diazo ketone solid supports and their application towards the enrichment of phosphorylated peptides. *Organic and Biomolecular Chemistry*, **2009**, 7, 3291-3299.
45. Hewlett, N. M.; Hupp, C. D.; Tepe, J. J., Reactivity of oxazol-5-(4H)-ones and their application toward natural product synthesis. *Synthesis*, **2009**, 17, 2825-2839.
46. Nguyen, T. N. T.; Tepe, J. J., Preparation of hymenialdisine, analogs and their evaluation as kinase inhibitors. *Current Medicinal Chemistry*, **2009**, 16, 3122-3143.
47. Tepe, Jetze J., Natural Product Inspired Small Molecular Scaffolds in Anticancer Therapy. *Current Bioactive Compounds*, **2009**, 5, 1.
48. Kahlon, Daljinder K.; Lansdell, Theresa A.; Fisk, Jason S.; Tepe, Jetze J., Structural activity relationship of functionalized *trans*-imidazolines as potent inhibitors of interleukin-6 production. *Bioorganic & Medicinal Chemistry*, **2009**, 17, 3093-3103.
49. Mosey, Robert A.; Tepe, Jetze J., New Synthetic Route to Access ( $\pm$ ) Salinosporamide A via an Oxazolone Mediated Ene-type reaction. *Tetrahedron Letters* **2009**, 50, 295-297.
50. Kahlon, Daljinder K.; Lansdell, Theresa A.; Fisk, Jason S.; Hupp, Christopher D.; Friebe, Timothy L.; Hovde, Stacy; Jones, A. Daniel; Dyer, Richard D.; Henry, R. William; Tepe, Jetze J., Nuclear Factor- $\kappa$ B Mediated Inhibition of Cytokine Production by Imidazoline Scaffolds. *Journal of Medicinal Chemistry*, **2009**, 52, 1302-1309.
- Article highlighted in: *Science-Business eXchange* **2009**, 2, 18.
51. Hupp, Christopher D.; Tepe, Jetze J., Total synthesis of a marine alkaloid from the Tunicate *Dendrodoa grossularia*. *Organic Letters*, **2008**, 10, 3737-3739.
52. Mosey, Robert A.; Tepe, Jetze J., Stereocontrolled synthesis of quaternary substituted amino acids using oxazolones. *Tetrahedron Asymmetry*, **2008**, 19, 2755-2762.
53. Mosey, Robert A.; Fisk, Jason S.; Friebe, Timothy L.; Tepe, Jetze J., Synthesis of tert-Alkyl Amino Hydroxy Carboxylic Esters via an Intermolecular Ene-type Reaction of Oxazolones and Enol Ethers. *Organic Letters*, **2008**, 10, 825-828.
54. Palumbo, Amanda M.; Tepe, Jetze J.; Reid, Gavin E., Mechanistic Insights into the Multistage Gas-Phase Fragmentation Behavior of Phosphoserine- and Phosphothreonine-Containing Peptides. *Journal of Proteomic Research* **2008**, 7, 771-779.
55. Fisk, Jason S.; Tepe, Jetze J., Intermolecular Ene Reactions Utilizing Oxazolones and Enol Ethers. *Journal of the American Chemical Society* **2007**, 129, 3058-3059.
56. Fisk, Jason S.; Mosey, Robert A.; Tepe, Jetze J., The Diverse Chemistry of Azlactones. *Chemistry Society Reviews* **2007**, 36, 1432-1440.
57. Sharma, Vasudha; Hupp, Christopher D.; Tepe, Jetze J., Enhancing the efficacy of chemotherapeutic drugs by small molecule inhibition of NF- $\kappa$ B and checkpoint kinases. *Current Medicinal Chemistry* **2007**, 14, 1061-1074.
58. Sharma, Vasudha; Peddibhotla, Satyamaheshwar; Tepe, Jetze J., Sensitization of Cancer Cells to DNA Damaging Agents by Imidazolines. *Journal of the American Chemical Society*. **2006**, 128, 9137-9143.
59. Sharma, Vasudha; Tepe, Jetze J., Diastereochemical Diversity of Imidazoline Scaffolds via Substrate Controlled TMSCl Mediated Cycloaddition of Azlactones. *Organic Letters*, **2005**, 7, 5091-5094.

60. Keni, Manasi; Tepe, Jetze J., One-pot Friedel-Crafts/Robinson-Gabriel Synthesis of Oxazoles Using Oxazolone Templates. *Journal of Organic Chemistry* **2005**, *70*, 4211-4213.
61. Sharma, Vasudha; Lansdell, Theresa A.; Peddibhotla, Satyamaheshwar; Tepe, Jetze J., Sensitization of Tumor Cells towards Chemotherapy: Enhancing the Efficacy of Camptothecin by Novel Imidazolines. *Chemistry & Biology* **2004**, *11*, 1689-1699.
62. Peddibhotla, Satyamaheshwar; Tepe, Jetze J., Stereoselective Synthesis of Highly Substituted  $\alpha^1$ -Pyrrolines: Exo Selective 1,3- Dipolar Cycloaddition Reactions with Azlactones. *Journal of the American Chemical Society* **2004**, *126*, 12776-12777.
63. Sharma, Vasudha; Tepe, Jetze J., Potent Inhibition of Checkpoint Kinase Activity by a Hymenialdisine-derived Indoloazepine. *Bioorganic & Medicinal Chemistry Letters*. **2004**, *14*, 4319-4321.
64. Sharma, Vasudha; Lansdell, Theresa A.; Jin, Guangyi; Tepe, Jetze J., Inhibition of Cytokine Production by Hymenialdisine Derivatives. *Journal of Medicinal Chemistry* **2004**, *47*, 3700-3703.
65. Lansdell, Theresa A.; Tepe, Jetze J., Isolation of Phosphopeptides using Solid Phase Enrichment. *Tetrahedron Letters* **2004**, *45*, 91-93.
66. Peddibhotla, S.; Tepe, J. J., Multicomponent Synthesis of Highly Substituted Imidazolines via a Silicon Mediated 1,3-Dipolar Cycloaddition. *Synthesis* **2003**, *9*, 1433-1440.
67. Peddibhotla, Satyamaheshwar; Cheng, Zigang; DellaPenna, Dean; Tepe, Jetze J., Efficient Two-step Synthesis of Methylphytylbenzoquinones: Precursor Intermediates in the Biosynthesis of Vitamin E. *Tetrahedron Letters* **2003**, *44*, 237-239.
68. Anderson, Kevin W.; Tepe, Jetze J., Trifluorosulfonic Acid Catalyzed Friedel-Crafts Acylation of Aromatics with  $\beta$ -Lactams. *Tetrahedron*, **2002**, *58*, 8475-8481.
69. Peddibhotla, Satyamaheshwar; Jayakumar, S.; Tepe, Jetze J., Highly Diastereoselective Multicomponent Synthesis of Unsymmetrical Imidazoline Scaffolds. *Organic Letters* **2002**, *4*, 3533-3535.
70. Anderson, Kevin W.; Tepe, Jetze J., First Intermolecular Friedel-Crafts Acylations with  $\beta$ -Lactams. *Organic Letters* **2002**, *4*, 459-461.
71. Tepe, Jetze J.; Kosogof, Christi, and Williams, Robert M., "DNA Interstrand Cross-link Formation by Reductive Activation of Dehydropyrrolizidine Progenitors", *Tetrahedron* **2002**, *58*, 3553-3559.
72. Beckenbauer, Louis, Tepe, Jetze J., Eastman, R.A. Mixer, P., Williams, Robert. M and Reeves, Raymond, "Vascular Leak Syndrome and Drug Design: Insights from FR900482 and FK317", *Chemistry & Biology* **2002**, *9*, 427-441.
73. Kosogof, Christi, Tepe, Jetze J. and Williams, Robert M, "DNA Cross-linking by a Phototriggered Pyrrolic Progenitor developed from Monocrotaline", *Tetrahedron Letters* **2001**, *42*, 6641-6643.
74. Beckenbauer, Louis, Tepe, Jetze J. JCullison, J., Reeves, Raymond and Williams, Robert M., "FR900482 Class of Anti-Tumor Drugs Cross-links Oncoprotein HMG I/Y to DNA *in vivo*", *Chemistry & Biology* **2000**, *7*, 805-812.
75. Tepe, Jetze J. and Williams, Robert M., "Reductive Activation of a Hydroxylamino Hemi-acetal Derivative of Dehydro -monocrotaline. DNA Cross-linking Studies", *Angewandte Chemie Int. Ed.* **1999**, *38*, 3501-3503.
76. Tepe, Jetze J. and Williams, Robert M., "DNA Cross-linking of a Photoactivated Dehydro- monocrotaline Progenitor", *Journal of the American Chemical Society* **1999**, *224*, 2450-2456.
77. Labroli, Marc. A, Macdonald, Timothy L., and Tepe, Jetze J.; "DNA Topoisomerase II Inhibitors", In: *Comprehensive Natural Products Chemistry*, E.T. Kool, ed., Elsevier-North Holland, Amsterdam, The Netherlands, Chap. 19, 1997.
78. Madalengoitia, Jose, S., Tepe, Jetze J., Werbovetz, Karl W., Lehnert, Eric K. and Macdonald, Timothy L., "Structure-Activity Relationship for DNA Topoisomerase II Induced DNA Cleavage by Azatoxin Analogs", *Bioorganic & Medicinal Chemistry* **1997**, *5*, 1807-1815.
79. Tepe, Jetze J., Madalengoitia, Jose S., Miller Slunt, Kelly, Werbovetz, Karl. W., Grant Spoor, Peter and Macdonald, Timothy L.: "Inhibition of DNA Topoisomerase II by Aza-elliptitoxins Functionalized in the Variable Substituent Domain", *Journal of Medicinal Chemistry* **1996**, *39*, 2188-2196.

## **US FILED PATENTS:**

1. US21 45448 Proteasome enhancers and uses thereof. August 10, 2021
2. US21 45446 Proteasome enhancers and uses thereof. August 10, 2021
3. US21 45440 Proteasome enhancers and uses thereof. August 10, 2021
4. US 2018-62623861A1 Pipecolic esters for inhibition of the proteasome, Jan. 30, 2019
5. US 2018/0282280A1 Quinoline-based proteasome inhibitors and uses thereof, Oct. 4, 2018.
6. US 62/539,049. Treatment of malignancies. July 31, 2018
7. US 62/515,403. Enhancement of proteasome activity for the treatment of neurodegenerative diseases. June 5, 2018
8. US Provisional patent 62/479,805. Quinoline-based proteasome inhibitors. March 31, 2017
9. US 8,552,206 B2. and European Patent: 03731545.4. NF- $\kappa$ B inhibitors and uses thereof. Oct. 8, 2013
10. US 8,252,942 B2. Substituted imidazoline compounds. Aug. 12, 2012
11. US 7,193,079 B1. Preparation of hymendialdisine derivates and use thereof. March 20, 2007
12. US 6,878,735 B2. Multi-substituted imidazolines and method of use thereof. April 12, 2005

## **INVITED SEMINARS at:**

1. ACS meeting, regional, Ypsylanti (June 7-10, 2022)
2. UCB Biopharma, Belgium (April 28, 2022)
3. Weizmann Institute of Science, Israel (January 19, 2022 – cancelled due to covid)
4. AbbVie Innovation Midwest Award, Chicago (October 19, 2021)
5. PharmD-2021 (September 20, 2021)
6. ACS National Meeting, Division of Medicinal Chemistry, Atlanta (August 25, 2021)
7. Ohio State University, College of Pharmacy (January 28<sup>th</sup>, 2021)
8. University of North Carolina, Eshelman School of Pharmacy (August 27, 2020)
9. Purdue University, Department of Medicinal Chemistry & Molecular pharmacology (March 5, 2020)
10. Michigan State University, Chemistry Department, Promotion Seminar (October 24, 2019)
11. International Myeloma Foundation, Award Ceremony, San Diego, California (December 1, 2018)
12. Breslin Cancer Institute, Lansing, MI (November 12, 2018)
13. 16<sup>th</sup> Annual Discovery on Target, Boston, MA (September 25, 2018)
14. Michigan State University, Cisplatin Symposium, East Lansing (August 3, 2018)
15. Wayne State University, Drug Discovery Symposium (October 14, 2017)
16. *Keynote lecture* at MedChem & CADD 2016, Phoenix, Arizona (December 2016)
17. Michigan State University, Department of Pediatrics and Human Development (April 6, 2016)
18. Sparrow Cancer Center, Lansing, Michigan (March 21, 2016)
19. Lemmon-Holton Cancer Pavilion, Spectrum Health, Grand Rapids, Michigan (January 13, 2016)
20. MedChem & CADD 2015, Atlanta, (November 2, 2015)
21. Drug Discovery & Therapy, World Congress 2015, Boston, Massachusetts (July 24, 2015)
22. Drug Discovery Seminar Series, MSU Pharmacology & Toxicology (January 16, 2015)
23. MedChem & CADD 2014, San Francisco, (December 8, 2014)
24. Drug Discovery USA, Boston Massachusetts (October 21, 2014)
25. University of Pittsburgh, Department of Pharmaceutical Sciences (September 16, 2014)
26. Fusion Conference, Drug Discovery Re-invented, Scottsdale, Arizona (October 16, 2013)
27. MedChem & CADD 2013, Las Vegas, Nevada (October 15, 2013)
28. Colorado State University, Williams Symposium (September 28, 2013)
29. Drug Discovery & Therapy, World Congress 2013, Boston, Massachusetts (June 6, 2013)
30. University of Illinois at Chicago (November 27, 2012)
31. Latest Trends in Organic Synthesis, Ontario CAN (August 12, 2012)
32. University of Virginia, Macdonald Symposium (April 27, 2012)
33. Washington University, School of Medicine (May 5, 2011)
34. Michigan State University, Pharmacology and Toxicology (January 12, 2011)
35. Butler University (March 26, 2010)



36. National Institutes of Health, (October 2, 2009)
37. University of Minnesota (July 1, 2009)
38. CERMAC, Symposium on Chemical Biology (March 20, 2009)
39. Wayne State University (February 18, 2009)
40. BioFine USA, Life Science Conference, FL (December 2, 2008)
41. University of Utah, (October 9, 2008)
42. Breslin Cancer Institute (January 18, 2008)
43. MSU, Breast Cancer Group (October 5, 2007)
44. Andrews University (March 1, 2007)
45. Central Michigan University (September 25, 2006)
46. Michigan State University, Carcinogenesis (September 19, 2006)
47. Michigan 21<sup>st</sup> Century Job Fund (August 15, 2006)
48. Case Western University (January 19, 2006)
49. University of Pittsburg (November 3, 2005)
50. Chamber of Commerce Japan, Seminar Tour with Governor Granholm (July 25)
51. Kyowa Hakko Co, Japan (July 24, 2005)
52. Gordon conference, Heterocyclic Chemistry (July 6, 2005)
53. SUNY at Buffalo/Roswell Cancer Institute (May 16, 2005)
54. Colorado State University (May 3, 2005)
55. Scripps Research Institute (May 2, 2005)
56. University of California at Riverside (April 29, 2005)
57. University of California at San Diego (April 28, 2005)
58. University of Maryland (March 31, 2005)
59. University of Delaware (March 17, 2005)
60. Pennsylvania State University (March 14, 2005)
61. SUNY at Buffalo (March 9, 2005)
62. University of Florida, Heterocyclic Conf. (February 27 -March 2, 2005)
63. Indiana University (November 29, 2004)
64. Michigan State University-Frontiers in Science (December 10, 2004)
65. University of Vermont (November 19, 2004)
66. University of Wisconsin-Madison (November 12, 2004)
67. Northwestern University (November 11, 2004)
68. Colgate University (October 12, 2004)
69. Wayne State University (October 6, 2004)
70. Michigan State University-MSU Foundation (May 26, 2004)
71. American Cancer Society- opening ceremony "Rely-for-Life" Waterloo, IN (May 15)
72. NIH/NCI- Division of Drug Development (February 13, 2004)
73. Oakland University (January 21, 2004)
74. 19<sup>th</sup> International Congress of Heterocyclic Chemistry (August 10-15, 2003)
75. Ohio State University (February 27, 2003)
76. Cleveland State University (April 11, 2002)
77. Eastern Michigan University (March 27, 2001)
78. St. Clouds University (March 4, 2001)

**CURRENT GRADUATE STUDENTS in Tepe Lab:**

Grace Hubbell ( <i>total synthesis &amp; medicinal chemistry</i> )	(Fall 2017 – present)
Taylor Fiolek ( <i>pharmacology</i> )	(Fall 2017 – present)
Allison Vanecek ( <i>medicinal chemistry &amp; pharmacology</i> )	(Fall 2018 – present) – on NIH DEI fellowship
Sophia Staerz ( <i>medicinal chemistry &amp; pharmacology</i> )	(Fall 2018 – present) – on NIH T32 fellowship
Konika Konika ( <i>total synthesis &amp; medicinal chemistry</i> )	(Fall 2019 – present)
Dare George ( <i>total synthesis &amp; medicinal chemistry</i> )	(Fall 2019 – present) – on NIH T32 fellowship

Charles Anamoah ( <i>medicinal chemistry</i> )	(Fall 2019 – present)
Daniel Colombani-Garay ( <i>medicinal chemistry</i> )	(Fall 2020 – present) – on NIH DEI fellowship
Kyra Dvorak ( <i>total synthesis &amp; medicinal chemistry</i> )	(Fall 2020 – present)
Evan Savelson ( <i>total synthesis &amp; synthetic methodology</i> )	(Fall 2020 – present)
Bahareh Ghaffari ( <i>medicinal chemistry &amp; bioorganic</i> )	(Spring 2021- present)
Sydney Cobb ( <i>medicinal chemistry &amp; bioorganic</i> )	(Fall 2021- present)
Shannon Cartwright ( <i>medicinal chemistry &amp; bioorganic</i> )	(Fall 2021- present)

**CURRENT SUPPORT STAFF in Tepe Lab:**

Christi Harris – laboratory technician (Spring 2020-present)

**FORMER STUDENTS:**

**POST-DOCTORAL STUDENTS and SABBATICAL VISITS TEPE LAB: Current position**

Prof. Robert Mosey	(2019- sabbatical)	- Lake Superior State University
Prof. Timothy Friebe	(2017-sabbatical)	- Eastern Michigan University
Daljinder Kahlon	(2007-2009)	- Nalco Energy Services
Jayakumar Warriar	(2003-2004)	- Bristol Myers Squibb
Guangyi Jin	(2002-2003)	- Research Scientist UCSD Cancer Center
Prof. Timothy Friebe	(2007-2008 sabbatical)	- Eastern Michigan University

**17 PhD STUDENTS GRADUATED FROM TEPE LAB: Current position**

Katarina Keel	(PhD 2021)	- Scientist, Eli Lilly
Shafaat Md Mehedi	(PhD 2020)	- Scientist, Hansohbio
Evert Njomen*	(PhD 2019)	- Post-doctoral (Prof. Cravatt, Scripps Research Institute)
Corey Jones	(PhD 2019)	- Scientist, Pfizer
Matt Giletto	(PhD 2017)	- Scientist, MSU, Medicinal Chemistry Center
Travis Bethel	(PhD 2017)	- Assistant Professor, Minnesota State University
Nicole Hewlett	(PhD 2014)	- Scientist, Dow Chemical Co.
Michael Kuszpit	(PhD 2013)	- Scientist, Ash Stevens – Piramal Pharma Solutions
Rahman Saleem	(PhD 2010)	- Associate Professor, Lahore University
Thu Nguyen	(PhD 2010)	- Assistant Professor, Lake Superior State University
Robert Mosey	(PhD 2010)	- Associate Professor, Lake Superior State University
Amanda Palumbo	(PhD 2009)	- Scientist, Dow Corning
Jason Fisk	(PhD 2009)	- Senior Scientist, Dow Chemical Co.
Christopher Hupp	(PhD 2009)	- co-Director, X-Chem INC
Samantha Frawley	(PhD 2009)	- Lecturer Lyman Briggs College
Vasudha Sharma	(PhD 2005)	- Research Professor, University of Florida
Mahesh Peddibhotla	(PhD 2004)	- Research Professor, University of Florida

\*Evert Njomen is the 2021 recipient of the HHMI Hanna H. Gray Fellowship to increase diversity in the biomedical research community.

**6 MS STUDENTS GRADUATED FROM TEPE LAB: Current position**

Lauren Azevedo	(MS 2014)	- Physician, Michigan State University
Micah Luderer	(MS 2011)	- Physician MD/PhD, Washington University-St. Louis
Brandon Dutcher	(MS 2011)	- Scientist, Chromatech Inc.
Ke Qu	(MS 2011)	- Graduate Student University of Illinois, Urbana-Champaign
Manasi Keni	(MS 2005)	- Research assistant Pacific Northwest National Laboratory
Kevin Anderson	(MS 2003)	- Scientist, Hoffmann-LaRoche

### 23 UNDERGRADUATES WORKED IN THE TEPE LAB:

Noura Massri (Spring 2017-2018)	Jake Claes (Spring 2009-2010)	Lauren Stanford (Summer 2004)
Kyle Truskowski (2016-2017)	Matthew Lyon (Fall 2008-2009)	Amanda Palumbo (Summer 2004)
Ben Heriford (Fall 2015-2017)	Amanda Simon (Fall 2008)	Brian Carey (Summer 2002)
Dajashinair Howard (Fall 2013-2016)	Sarah Grojean (Spring 2007)	Jeffrey Hatch (Summer 2002)
Dillon Cogan (Spring 2012 – 2013)	Joseph F. Prano (Spring 2007)	Sam Molina (Spring 2002)
Jake Ludwig (Fall 2011- Spring 2014)	Maho Hibino (Fall 2006)	Michael Campian (Spring 2002)
Peter Jacobson (Spring 2010)	Brandon Dutcher (Spring 2005)	Tanaya Everson (Summer 2001)
Philip Lukulay (Fall 2009-2010)	Stephen Shaw (Spring 2002-2004)	

### Current Student Training Grants:

George, Dare: IPSTP student training grant NIH T32 GM142521; PI Neubig, co-PI Dorrance	08/15/21-07/14/22
Daniel Colombani-Garray NIH R01 AG066223-01A1-DEI <i>Suppl.</i> ; PI Tepe	03/15/19-05/31/23
Allison Vaneck NIH R01 AG066223-01A1-DEI <i>Suppl.</i> ; PI Tepe	12/01/21-05/31/23

### Previous Student Training Grants:

Sophia Staerz: IPSTP student training grant NIH T32 GM092715; PI Neubig	08/15/19-07/14/21
Taylor Fiolek: IPSTP student training grant NIH T32 GM092715; PI Neubig	08/15/17-07/14/19
Evert Njomen: IPSTP student training grant NIH T32 GM092715; PI Neubig	08/15/15-07/14/17

### PREVIOUS RESEARCH SUPPORT

IMF International Myeloma Foundation Award Tepe, PI; Title: Targeting c-Myc degradation to treat myeloma Total funds: \$80,000	01/01/19-03/31/20
NIH 1R21AI117018-01A1 (PI, Abramovitch, Co-PI Tepe, 50:50) Title: Non-competitive proteasome inhibitors to treat chronic, drug-resistant tuberculosis Total direct costs: \$275,000 (total direct to Tepe \$137.5K)	08/20/16-07/31/19
MSU Discretionary Funding Initiative (PI, Tepe) Title: Redesigning phenothiazine as proteasome activators for the treatment of neurodegenerative diseases Total funds: \$50K (total direct costs \$50K)	04/17/18 – 4/16/19
MTRAC- Michigan Translational Research and Commercialization (co-PI Tepe, 50%) Title: Development of new treatments for canine histiocytic sarcomas Total funds: \$100K (total direct costs \$100K)	11/05/17– 10/30/19
CTSI - Clinical and Translational Science Institute (PI, Tepe) Title: Proof-of-concept studies for a new approach to treat neurodegenerative diseases Total funds: \$25K (total direct costs \$25K)	04/15/18 - 04/14/19
MSU- Molecule Discovery Grant pilot program (co-PI, Tepe) Title: Exploration of viability of proteasome inhibitors with alternative mechanisms Total funds: \$25K (total direct costs \$25K)	03/03/18 - 03/02/19
NIH 1R01GM110195-01 (PI, Neubig, Co-I/Tepe 95:5) Title: Small molecule stabilizers of RGS protein expression	04/01/14 - 03/31/18

Total direct costs to Tepe: \$15,000

Strategic Partnership Grant 14-SPG-2966 (PI, Abramovitch, Co-PI Tepe, 50:50) Title: Non-competitive proteasome inhibitors to treat chronic, drug-resistant tuberculosis Total direct costs: \$400,000 (total direct to Tepe \$200K)	06/01/15 - 05/31/18
SPG-CNS match S14-SPG-2966 (PI, Tepe) Title: Non-competitive proteasome inhibitors to treat chronic, drug-resistant tuberculosis Total direct costs: \$40,000	06/01/15 - 05/31/18
MSU- Molecule Discovery Grant pilot program (PI, Tepe) Title: Development of drug-like TCH-165 derivatives Total direct costs: \$10,000	03/03/17 - 03/02/18
MSU- Clinical and Translational Science Institute (PI, Tepe) Title: Evaluation of the translational effect of TCH-165 on non-responsive and relapsing MM patient samples Total direct costs: \$9,000	03/03/17 - 03/02/18
MTRAC- Michigan Translational Research and Commercialization (PI, Yuzbasiyan-Gurkan) Title: Development of new treatments for canine histiocytic sarcomas Total direct costs: \$25,000	12/30/16 - 12/29/17
NIH 1R21CA182926--02 (PI, Tepe) Title: Characterization of non-competitive proteasome binding Total cost: \$346K (total direct costs \$239K)	02/11/14 - 01/31/16
International Myeloma Foundation (PI, Tepe) Title: Validation of non-competitive proteasome modulation for multiple myeloma Total cost: \$80K (total direct costs \$72K)	01/02/13 - 01/01/14
NIH 1R01CA142644-01 (PI, Tepe) Title: Inhibition of interleukin-6 production for the treatment of multiple myeloma Total cost: \$825K (total direct costs \$560K)	04/01/10 - 03/31/14
Multiple Myeloma Research Foundation, Senior Award (PI, Tepe) Title: Development of allosteric proteasome inhibitors for the treatment of MM Total cost: \$200K (total direct costs \$180K)	05/15/10 - 04/14/12
MIIE ( <i>Michigan Initiative for Innovation &amp; Entrepreneurship</i> ) Award (PI, Tepe) Title: Pre-clinical development of non-covalent proteasome inhibitors for the treatment of multiple myeloma. Total direct cost: \$57K	07/01/09 - 06/30/10
Multiple Myeloma Research Foundation, Senior Award (PI, Tepe) Title: Phosphoproteomic analysis of NF-kappaB in multiple myeloma Total cost: \$200K (total direct costs \$180K)	06/01/08 - 05/30/10
NIH R01 GM071549-01 (PI, Tepe) Title: New Methods in Phosphoproteomics Total cost: \$1,196K (total direct costs \$800K)	08/01/04 - 07/30/09
Michigan Universities Commercialization Initiative (PI, Tepe) Title: Advancing NF-kB inhibitors with novel mechanism of action through pre-clinical development Total direct cost: \$150K	10/08/07 - 07/31/09
TCH Pharmaceuticals, INC (PI, Tepe) Title: Cellular Activity and Inhibition of NF-κB Total direct cost: \$120K	06/01/06 - 07/31/08
Center Grant: Center for Cancer Proteomic (PI, Tepe)	08/16/06 - 10/30/08

Title: Phosphoproteomic analysis of cancer signaling

Total direct cost: \$353K

American Cancer society RSG CDD-106972 (PI, Tepe)

01/01/04 - 12/31/08

Title: Chemopotential of Anticancer Drugs by Novel Imidazolines

Total costs \$800K (total direct cost \$720K)

Strategic Partnership Grant (PI, Tepe)

06/01/04 - 05/31/07

Title: Enhancement of efficacy of chemotherapeutic drugs

Total direct cost: \$280K